Ocular Therapeutix, Inc.
OCUL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 9% | 13.5% | 18.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.2% | 91% | 91.2% | 89.9% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -276.4% | -113.6% | -120.2% | 5.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -303.7% | -138.1% | -138% | -15.1% |
| EPS Diluted | -1.22 | -1.02 | -0.97 | -0.98 |
| % Growth | -19.6% | -5.2% | 1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |